The global anti-epileptic drugs for the pediatrics market is anticipated to grow at a considerable CAGR of 4.4% during the forecast period (2022-2028). Due to the patent expiration of key brands, generic competition has exploded for antiepileptics, and it will continue to drive down the price of branded treatments in the future. Along with its excellent efficacy, Lyrica was the most popular antiepileptic drug. Antiepileptic drugs like retigabine and perampanel were recently approved, and they work by targeting new molecular targets. Additionally, certain problems such as a lack of disease information in developing nations, a scarcity of medical facilities in low and middle-income countries, and a reluctance to deploy epilepsy drugs have limited the market. In addition, the lack of a proper supply chain for epilepsy pharmaceuticals, as well as treatment side effects, is projected to impede market expansion. For instance, in January 2018, the good results of phase 3 clinical trial of Zogenix Inc.'s Antiepileptic Drugs AED (FINTEPLA) under development have been announced. During the forecast period, this constant research and development to satisfy unmet demands are expected to boost the anticonvulsants medicines market forward. For instance, in 2018 FYCOMPA (perampanel) CIII, an antiepileptic medicine developed by Eisai Inc., has been approved by the US Food and Drug Administration (FDA) for monotherapy and adjunctive use in pediatric patients aged 4 years and older with partial-onset seizures (POS) with or without secondarily generalized seizures.
Browse the full report description “Global Anti-epileptic Drugs for Pediatrics Market Size, Share & Trends Analysis Report by Drug Type (1stGeneration, 2nd Generation, and 3rd Generation), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast 2022-2028“at https://www.omrglobal.com/industry-reports/anti-epileptic-drugs-for-pediatric-market
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- including Bausch Health Co. Inc., Cephalon Inc., GlaxoSmithKline Plc, Janssen Pharmaceuticals, Pfizer Inc., and others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Anti-epileptic Drugs for Pediatrics Market Report Segment
By Drug Type
By Distribution Channel
Global Anti-epileptic Drugs for Pediatrics Market Report Segment by Region
North America
Europe
Rest of Europe
Rest of the World